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OBJECTIVE — The objective of this study was to create a tool that predicts the risk of
mortality in patients with type 2 diabetes.
RESEARCH DESIGN AND METHODS — This study was based on a cohort of 33,067
patients with type 2 diabetes identiﬁed in the Cleveland Clinic electronic health record (EHR)
who were initially prescribed a single oral hypoglycemic agent between 1998 and 2006. Mor-
tality was determined in the EHR and the Social Security Death Index. A Cox proportional
hazards regression model was created using medication class and 20 other predictor variables
chosen for their association with mortality. A prediction tool was created using the Cox model
coefﬁcients. The tool was internally validated using repeated, random subsets of the cohort,
which were not used to create the prediction model.
RESULTS — Follow-upinthecohortrangedfrom1dayto8.2years(median28.6months),and
3,661 deaths were observed. The prediction tool had a concordance index (i.e., c statistic) of 0.752.
CONCLUSIONS — We successfully created a tool that accurately predicts mortality risk in
patients with type 2 diabetes. The incorporation of medications into mortality predictions in
patients with type 2 diabetes should improve treatment decisions.
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P
atients with type 2 diabetes have an
increased risk of mortality (1–4),
andtoolsforpredictingoverallmor-
tality in diabetic patients are lacking.
Tools for predicting the risk of cardiovas-
cular disease (CVD) have been created
and assist physicians in the prevention of
CVD among patients with type 2 diabetes
(5–8). However, these tools do not con-
sidertheriskofall-causemortality.Prevent-
ing a myocardial infarction is important
but not if the patient dies prematurely
from kidney disease. Treating each dis-
ease in isolation is a strategy that fails to
consider the overall effect to the patient.
Scores have been created to adjust for di-
abetes severity and other comorbid con-
ditions when mortality is studied (9,10).
However, these indexes do not provide
overall mortality predictions and there-
fore are of limited use in routine clinical
practice. Furthermore, existing prediction
tools do not adjust for a patient’s current
therapy. Speciﬁc diabetes medications may
decrease the risk of one complication while
increasingtheriskofotheroutcomes.Tools
are needed to help clinicians tailor therapy
toindividualpatientstominimizemortality
risk on the basis of characteristics of the pa-
tient, his or her disease, and the available
treatment options. The purpose of this
study was to create a mortality risk calcula-
torforpatientswithtype2diabetesthatcan
be used to aid in treatment decisions.
RESEARCH DESIGN AND
METHODS— This study was con-
ducted on a retrospective cohort of pa-
tients with type 2 diabetes whose data
werecollectedforclinicalandadministra-
tive purposes in the electronic health
record(EHR)atClevelandClinic.Theco-
hort began in 1998, and follow-up data
were obtained through 2006.
Eligibility criteria at baseline
Baselinewasdeﬁnedasthedateoftheﬁrst
prescription for a qualifying oral antidia-
betic agent in an eligible patient. Because
we are interested in patients with type 2
diabetes, the cohort was limited to pa-
tients at least 18 years of age with a diag-
nosis of diabetes. Patients with diabetes
were identiﬁed if they had a single diag-
nosisofdiabetesinthe“History”or“Prob-
lemList”sectionsoftheirchart.Toreduce
the chance of misclassiﬁcation due to
“rule out” diagnoses, we required two oc-
currences of “diabetes” for patients with
diabetes identiﬁed from the “encounter
diagnosis” section. The following codes
from the ICD-9 were used to identify pa-
tients with diabetes: 250–250.99, 357.2,
362.01, 362.02, 366.41, and 648.01–
648.04.
The cohort was further limited to pa-
tientswhowereprescribedasingleoneof
the four most common types of oral hy-
poglycemic agents: sulfonylureas (SFUs),
meglitinides (MEGs), biguanides (BIGs),
or thiazolidinediones (TZDs). Patients
prescribed -glucosidase inhibitors were
excluded because of an inadequate sam-
ple (n  149). Patients with prescriptions
for multiple oral agents at baseline were
excluded because of the substantial num-
ber of possible two- and three-drug (10)
combinations.
Exclusions
Polycystic ovarian syndrome is some-
times treated with a biguanide and could
beconfusedwithdiabetes.Noninsulinin-
jectable medications are used infre-
quently in the treatment of type 2
diabetes, and the patients receiving these
medicationsmaybefundamentallydiffer-
ent. Therefore, patients with polycystic
ovarian syndrome (ICD-9 256.4) and pa-
tientsprescribednoninsulininjectabledi-
abetes medications at baseline were
excluded.
Outcome
Mortality was determined in the EHR and
with linkage to the Social Security Death
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ceased per the SSDI or the EHR but who
continued to have vital statistics entered
into the EHR were counted as alive.
Predictor variables
The following variables were included in
the model because of their independent
associations with mortality in the litera-
ture: estimated glomerular ﬁltration rate
(GFR), A1C, BMI, systolic blood pressure
(SBP), diastolic blood pressure (DBP),
HDL and LDL cholesterol, triglycerides,
history of congestive heart failure (CHF),
history of coronary heart disease, smok-
ing status, use of concomitant medica-
tions (insulin, ACE inhibitor/angiotensin
receptor blocker [ARB], aspirin, clopido-
grel, or lipid-lowering drug), new diabe-
tes, sex, race, age, and oral medication
class. Values for all of the predictor vari-
ables were extracted from the EHR. GFR
was calculated from serum creatinine us-
ingthesimpliﬁedequationfromtheMod-
iﬁcation of Diet in Renal Disease Study
Group (11). BMI was calculated using the
standard equation (weight in kilograms
dividedbythesquareofheightinmeters).
The baseline date was deﬁned as the date
of the ﬁrst prescription for an oral hypo-
glycemic agent in a qualiﬁed individual.
The baseline value for the predictor vari-
ableswasdeﬁnedasthevalueonthebase-
line date or the most recent historical
value.Ifnohistoricallaborvitalvaluewas
available then the value closest to the
baselinedateupto21daysintothefuture
was deﬁned as the baseline. Patients were
considered to be newly diabetic if they
had been seen before their baseline date
by either an endocrinologist or primary
carephysicianatClevelandClinicanddid
nothaveadiagnosisofdiabetesenteredin
the EHR at that time.
Interactions
Alimitednumberofinteractionswereex-
plored for inclusion in the predictive
model but for parsimony were only in-
cluded if they were statistically signiﬁcant
(P  0.05). The following interactions
were investigated in the model:
Medication class  GFR and medica-
tion class  age. The medication class in-
teractions with GFR and age were
included because of the precautions ad-
vised for use of biguanides in older adults
and in patients with renal dysfunction
(12).
Sex  race. The interaction for sex
and race was explored because of the
higher risk of coronary heart disease seen
in black women (13).
Medication class  CHF. The interac-
tion between medication class and heart
failure was explored because of the pre-
cautionsadvisedforusingTZDsandBIGs
in patients with CHF (12).
Statistical methods
The analytic dataset was built using SAS,
version 9.1. Missing values were imputed
using Multiple Imputation by Chained
Equations package, version 1.16, for R
(14). Imputation was performed to max-
imize the available information and to re-
duce the potential bias introduced by
deletingincompleterecords.Theimputa-
tionwasperformedusingregressiontech-
niques that include all baseline patients
and all baseline variables as predictors
and without knowledge of the outcome.
Linearity assumptions of the ordinal and
continuous variables were relaxed by ﬁt-
ting the model using restricted cubic
splines.
A Cox proportional hazards regression
model was created with the predictor vari-
ablesandinteractionslistedabovewithtime
to death as the outcome. Statistical analyses
were performed using R for Unix, version
2.3.1 (15). The coefﬁcients from the ﬁtted
Cox model were also used to develop an
interactive Web-based tool that calculates
the predictions automatically. The Web-
based calculator is available from http://
www.clinicriskcalculators.org.
Tenfold cross-validation was used to
validate our modeling approach. With
this method, the data are randomly parti-
tioned into 10 equal segments. One seg-
ment(10%ofthedata)isextractedbefore
the prediction model is ﬁtted. The model
is ﬁtted with the remaining 90% of the
data, and the prediction accuracy is eval-
uated on the outcomes observed in the
10% subsample. The process is repeated
(10 times) until each segment of the data
has been used to assess the prediction ac-
curacy.Acalibrationcurvewascreatedby
plotting the quintiles of the predicted
probabilities on the observed estimates
for the entire cohort. The model was also
evaluated through the use of the concor-
dance index (i.e., c statistic). In this pro-
cess, the model is graded on its ability to
differentiate between all possible discor-
dant pairs of patients. (For example, pa-
tient 1 dies after 6 months in the cohort.
Patient 2 dies after 3 years in the cohort.
Does the predictive model correctly show
that patient 1 had a higher risk of death?)
Concordance indexes can vary between
0.5 (chance) and 1.0 (perfect prediction).
RESULTS— The ﬁnal cohort had a
sample size of 33,067 patients. Table 1
shows the characteristics of the cohort at
baseline by drug class. Overall, the pa-
tients were predominantly white with a
similar proportion of men and women.
Patients taking BIGs were younger, had
less heart failure, and were more likely to
have newly diagnosed diabetes compared
with patients taking the other drugs. Pa-
tients taking TZDs were the most likely to
be using insulin, whereas patients taking
MEGs had the lowest levels of LDL cho-
lesterol and triglycerides.
Cumulative mortality by drug class is
shown in Fig. 1. There were 1,958 pa-
tients followed for at least 5 years. The
median length of follow-up was 28.6
months (range 1 day–8.2 years). The
number of deaths per drug class were
799, 135, 2,220, and 507 for BIGs,
MEGs, SFUs, and TZDs, respectively.
The interaction between race and sex
was not found to be statistically signiﬁ-
cantandwasremovedfromthemodelfor
parsimony. The other interactions (med-
ication  GFR, medication  age, and
medication  CHF) were all statistically
signiﬁcant. The medication  CHF inter-
action was the least signiﬁcant of these
interactions and was removed from the
ﬁnal model to reduce the size of the ﬁnal
nomogram. Figure 2A and B shows the
paper-based nomogram for predicting
6-year survival (model coefﬁcients are
available in the supplemental table in an
online appendix, available at http://
dx.doi.org/10.2337/dc08-1047).
TheBIGswereassociatedwiththelow-
est risk of mortality in younger patients.
Because of the interactions between
medication with GFR and medication
with age, the medication associated with
the highest probability of survival varied
according to individual patient character-
istics.Asexpected,smokingandhighlev-
els of A1C were associated with lower
survival. LDL had a U-shaped relation-
ship with mortality. The lowest risk of
mortality was associated with an LDL of
150 mg/dl and increased with higher or
lower LDL levels.
Figure 3 shows the calibration curve
for the mortality prediction. The pre-
dicted survival was quite accurate at all
quintiles of mortality risk. The concor-
dance index for the survival prediction
was 0.752, which indicates that the no-
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identifying which patient had the highest
riskamongallpossiblediscordantpatient
pairs.
CONCLUSIONS— The prediction
tool created in this study was accurate in
predicting 6-year mortality risk among
patients with type 2 diabetes. The c statis-
ticof0.752indicatesgooddiscrimination
ability of this tool, and the calibration
curve shows that the prediction does not
signiﬁcantly overestimate or underesti-
mate risk. If the current prediction tool
performs well in other cohorts of patients
with type 2 diabetes, it offers clinicians a
tool for tailoring antidiabetes treatments
withtheaimofimprovingsurvivalamong
patients with type 2 diabetes.
We are not aware of other tools de-
signed to predict mortality in patients
withtype2diabetesintheclinicalsetting.
ItishopedthattherecentlypublishedDi-
abetes Complications Severity Index
(DCSI) will improve the ability to adjust
for the severity of type 2 diabetes in fu-
ture regression models predicting mor-
tality (9). However, the DCSI is not a
stand-alone prediction tool and is de-
signed to be used as a covariate in a
larger model. We did not have all of the
predictors necessary to add the DCSI
score to our model.
The widespread use of this tool may
be limited by the number of predictor
variables that we included in the model
and the requirement of GFR. We did not
attempt to reduce the model using vari-
able selection techniques (e.g., stepwise
regression) because the omission of insig-
niﬁcant predictors tends to harm predic- Figure 1—Mortality curve over time.
Table 1—Baseline characteristics of patients by drug class after imputation
BIG MEG SFU TZD Missing*
n 14,708 773 12,606 4,980
Continuous variables
Age 57.8  13.7 66.4  13.3 66.4  13.2 61.9  12.9 0 (0)
BMI 33.5  7.5 30.3  6.9 31.1  6.9 33.4  7.8 13,986 (42.3)
LDL (mg/dl) 110.1  39.0 94.2  36.2 107.4  39.2 107.1  40.7 17,347 (52.5)
HDL (mg/dl) 46.9  14.0 49.4  16.3 46.0  14.4 46.2  14.1 16,653 (50.4)
Triglycerides (mg/dl) 203.6  229.6 169.8  116.5 202.9  211.6 207.0  214.1 16,861 (51.0)
Categorical variables
Male sex 6,733 (45.8) 418 (54.1) 6,961 (55.2) 2,600 (52.2) 2 (0.01)
Caucasian 11,198 (76.1) 647 (83.7) 9,844 (78.1) 4,073 (81.8) 1,175 (3.6)
Heart failure 431 (2.9) 97 (12.5) 1,030 (8.2) 255 (5.1) NA
Insulin 1,934 (13.1) 214 (27.7) 1,371 (10.9) 1,568 (31.5) NA
Aspirin 3,566 (24.2) 243 (31.4) 3,171 (25.2) 1,325 (26.6) NA
Plavix 929 (6.3) 98 (12.7) 1,059 (8.4) 516 (10.4) NA
ACE/ARB 7,286 (49.5) 443 (57.3) 6,699 (53.1) 2,921 (58.7) NA
Cholesterol medication 7,098 (48.3) 409 (52.9) 5,630 (44.7) 2,911 (58.5) NA
New diabetic 4,578 (31.1) 37 (4.8) 1,002 (7.9) 399 (8.0) NA
Heart disease 1,533 (10.4) 147 (19.0) 1,791 (14.2) 688 (13.8) NA
Current smokers 2,310 (15.7) 74 (9.6) 1,795 (14.2) 757 (15.2) 8,195 (24.8)
History of stroke or transient
ischemic attack
591 (4.0) 64 (8.3) 715 (5.7) 264 (5.3) NA
GFR (ml/min) 60 1,875 (12.7) 293 (37.9) 3,501 (27.8) 1,329 (26.7) 10,702 (32.4)
Dataaremeans SDorn(%).n  33,067.Allofthebaselinecharacteristicsshowedsigniﬁcantdifferenceswhenstratiﬁedbydrugclass.*Numberofmissing
values before imputation. NA, not applicable.
Wells and Associates
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online version of the calculator will make
the model more user-friendly by calculat-
ing GFR automatically from serum creat-
inine and eliminating the need for the
paper nomogram. The online calculator
is available as mentioned earlier under
STATISTICAL METHODS.
This study has several other weak-
nesses that should be discussed. First,
there is the potential for misclassiﬁcation
bias surrounding the designation of the
baseline oral medication. Prescriptions
outside Cleveland Clinic are unknown,
and we did not assess for medication
changeswithinoursystem.However,in
a separate analysis of this cohort, we
found that 75% of patients were
treated with the same oral diabetes
medication throughout their time in the
cohort. A second weakness of the study
involvesthesubstantialamountofmiss-
ing data for some predictor variables.
However, the imputation techniques
used should help to limit the potential
bias caused by simply eliminating in-
complete records. Third, we were un-
able to accurately deﬁne the exact
duration of type 2 diabetes. Patients
whose diabetes was diagnosed on their
ﬁrst visit to Cleveland Clinic will not be
recognized as newly diabetic. However,
duration of diabetes is probably cap-
tured by the presence or absence of co-
morbidities and other variables such as
GFR. Diabetes complications may be
the most accurate reﬂection of diabetes
duration because the disease frequently
goes undetected for years after it ﬁrst
appears(17).Youngetal.(9)foundthat
duration of diabetes was not indepen-
dently predictive of mortality. In addi-
tion,thepresenceofcomorbidconditions
such as heart failure and stroke may be
underdocumented in the EHR. However,
there is no reason to suggest that the doc-
umentationwouldvaryaccordingtodrug
class.Tomaximizethepresenceorabsence
of baseline conditions, we included infor-
mation beyond documentation of ICD-9
codes. For instance, patients with a docu-
mentation of a coronary revascularization
procedure were considered to have a his-
tory of heart disease. Despite any possible
lack of documentation in the EHR, the
model performed very well. A ﬁnal weak-
ness could be the loss to follow-up that is
inevitableinthistypeofstudy.Fortunately,
we were able to link participants with the
SSDI, which should capture deaths of pa-
tients regardless of loss to follow-up at
Cleveland Clinic.
The major strengths of the study in-
clude the large sample size and cohort de-
sign. The good prediction accuracy
obtainedthroughthecross-validationofthe
model suggests strong internal validity of
theseresults.TheWeb-basedversionofthis
calculator provides the tool in an easily ac-
cessible format for clinical use. The current
model requires external validation before
the applicability of this model to other pa-
tient populations will be known.
Figure 2—Nomogram for predicting 6-year probability of survival. Instructions for using the nomogram are as follows. Estimate the patient’s GFR
from his or her most recent serum creatinine level. Locate the value of the patient’s age according to baseline medication and GFR in A, draw a line
straightupwardtothePointsaxistodeterminethenumberofpointscontributedbyage.Repeatthisprocessfortheothervariablesinthemodel.Sum
thepointsachievedforeachpredictorinA.RepeatthisprocessinB.Sumthepointsobtainedinbothpartsofthenomogram,andﬁndthistotalonthe
TotalPointsaxisatthebottomof B.Drawastraightlinedownfromthetotalpointsaxistodeterminetheprobabilityof6-yearsurvival.Animportant
point to note about nomograms is the U-shaped relationship. In this nomogram, for instance, the LDL cholesterol predictor variable has a U-shaped
relationship with the probability of survival. This is presented in the nomogram by having the direct relationship on one side of the scale and the
indirectrelationshipontheothersideofthescale.LDLcholesterollevelsfrom150to0areshownunderthescaleandhaveadirectrelationshipwith
survival, whereas LDL cholesterol values from 150 to 450 are shown on the top of the scale and have an indirect relationship with survival. In other
words,apatientwithanLDLcholesterolofexactly150hasthehighestprobabilityofsurvival,andastheLDLcholesterolgoesupordownfrom150,
the risk of mortality increases. An example of use of the nomogram is the following. A 50-year-old man with type 2 diabetes presents today for his
ﬁrstvisitatClevelandClinic.Thephysiciancaringforthepatient(Pt)wantstoknowtheriskofmortalityforthisspeciﬁcpatientoverthenext6years
ifheorsheprescribesaBIG.Herearethecharacteristicsforthispatientalongwiththecalculationusingthesurvivalnomogram:age50years,taking
BIG, GFR 60 ml/min (18 points); A1C 10.0% (3 points); BMI 35 kg/m
2 (0 points); systolic blood pressure 140 mmHg (0 points); diastolic blood
pressure80mmHg(3points);HDLcholesterol35mg/dl(6points);LDLcholesterol100mg/dl(1point);triglycerides200mg/dl(1point);malesex
(3 points); Caucasian (7 points); no heart disease (0 points); no heart failure (0 points); no smoking (0 points); no insulin (0 points); no ACE/ARBs
(5 points); not newly diabetic (10 points); aspirin, yes (0 points); no clopidogrel (0 points); and no lipid-lowering drugs (0 points). Total points 
57. Probability of 6-year survival 0.94. Nomogram calculator available online from http://www.clinicriskcalculators.org.
Figure 3—Validation of the survival prediction. Vertical bars represent the 95% CIs by quintile.
The 45° line represents a perfect prediction.
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